← Eichor
Study identifier: NCT07249775 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

A First-in-Human Study of FID-022 in Solid Tumor Patients

Condition: Pancreatic Cancer · Cancer Cachexia  ·  Sponsor: H. Lee Moffitt Cancer Center and Research Institute

PhaseN/A
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This observational study aims to (1) validate a multimodal artificial intelligence (AI) model for early detection of cancer-associated cachexia in pancreatic cancer patients and (2) assess the feasibility and acceptability of diet and exercise interventions for cachexia management. The study will use retrospective data from the Florida Pancreas Collaborative and prospective data from newly diagnosed patients at Moffitt Cancer Center.

This description comes directly from the study's public registry record.

Talk to the study team

Sanjukta Bhattacharjee  ·  813-745-0279  ·  Sanjukta.Bhattacharjee@moffitt.org

Always discuss trial participation with your own doctor first.

Locations (1)

Moffitt Cancer CenterTampa, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07249775